Synergy Pharmaceuticals to Present Abstract at Digestive Disease Week 2012

NEW YORK, May 15, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that a poster presentation will be given at the Digestive Disease Week 2012 Conference which is being held in San Diego, CA from May 19 through May 22, 2012.

The poster presentation is Sunday, May 20, 8:00 am to 5:00 pm at the San Diego Convention Center.

Poster Su1189: Identification of Cardinal Symptoms in Patients with Chronic Idiopathic Constipation (CIC). Alan Joslyn¹, Laura Barrow¹, Gary S. Jacob¹ and Jean Paty²

¹Synergy Pharmaceuticals, 420 Lexington Ave., Suite 1609, New York, NY, USA; ²PRO Consulting, 2100 Wharton Street, Suite 505, Pittsburgh, PA 15203

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's lead proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in CIC patients. In October, 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide to treat chronic idiopathic constipation. Plecanatide is also being developed to treat IBS-C, with the first trial in IBS-C patients planned for 2H2012. Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel diseases. More information is available at http://www.synergypharma.com.

Investor Contact Information:

Danielle Spangler
The Trout Group

(646) 378-2924